Observational studyThorax2022
Lung microbiota predict invasive pulmonary aspergillosis and its outcome in immunocompromised patients.
Observational study in Thorax, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 59 citations in OpenAlex.
- Clinical application of BALF-mNGS in immunocompromised and immunocompetent patients with suspected invasive pulmonary aspergillosis: differentiating infection from colonization, microbiome features, and clinical impact.Microbiology spectrum · 2026Article
- Empowering fungal infection research with single-cell RNA sequencing.Communications biology · 2026Review
- Article
- Aspergillus fumigatus in mechanically ventilated pneumonia- independent mortality risk and synergistic microbiome signatures from a multicenter mNGS cohort.BMC pulmonary medicine · 2026Article
- Article
- Gut-Lung Axis Microbiome Dysbiosis and Cross-Domain Network Analysis in Bronchiectasis Complicated by Invasive Pulmonary Aspergillosis.Infection and drug resistance · 2026Article
- Aspergillus fumigatus biology, immunopathogenicity and drug resistance.Nature reviews. Microbiology · 2025Review
- Characteristics and Clinical Significance of Gut Microbiota in Patients with Invasive Pulmonary Aspergillosis.Polish journal of microbiology · 2025Article
- Review
- Pathogenic profiles and lower respiratory tract microbiota in severe pneumonia patients using metagenomic next-generation sequencing.Advanced biotechnology · 2025Article
- The Microbiota-Human Health Axis.Microorganisms · 2025Review
- A Predictive Model for Pulmonary Aspergillosis in ICU Patients: A Multicenter Retrospective Cohort Study.Infection and drug resistance · 2025Article
- Lung-gut axis, intestinal microbiota, and pulmonary fibrosis: mechanisms and therapeutic potential.Frontiers in microbiology · 2025Review
- Immunocompromise and early-onset invasive pulmonary aspergillosis in viral pneumonia: a retrospective cohort study.Frontiers in public health · 2025Article
- Profiling Bacteria in the Lungs of Patients with Severe Influenza Versus COVID-19 with or without Aspergillosis.American journal of respiratory and critical care medicine · 2024Article
- One-Step Soft Agar Enrichment and Isolation of Human Lung Bacteria Inhibiting the Germination ofMicroorganisms · 2024Article
- Rethinking Aspergillosis in the Era of Microbiota and Mycobiota.Mycopathologia · 2024Review
- Gut-Derived Short-Chain Fatty Acids and Macrophage Modulation: Exploring Therapeutic Potentials in Pulmonary Fungal Infections.Clinical reviews in allergy & immunology · 2024Review
- Article
- Alterations of lung microbiota in lung transplant recipients with pneumocystis jirovecii pneumonia.Respiratory research · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleRecent studies have revealed that the lung microbiota of critically ill patients is altered and predicts clinical outcomes. The incidence of invasive fungal infections, namely, invasive pulmonary aspergillosis (IPA), in immunocompromised patients is increasing, but the clinical significance of variations in lung bacterial communities is unknown.
objectivesTo define the contribution of the lung microbiota to the development and course of IPA. METHODS AND MEASUREMENTS: We performed an observational cohort study to characterise the lung microbiota in 104 immunocompromised patients using bacterial 16S ribosomal RNA gene sequencing on bronchoalveolar lavage samples sampled on clinical suspicion of infection. Associations between lung dysbiosis in IPA and pulmonary immunity were evaluated by quantifying alveolar cytokines and chemokines and immune cells. The contribution of microbial signatures to patient outcome was assessed by estimating overall survival. MAIN
resultsPatients diagnosed with IPA displayed a decreased alpha diversity, driven by a markedly increased abundance of the
conclusionsOur results reveal the lung microbiota as an understudied source of clinical variation in patients at risk of IPA and highlight its potential as a diagnostic and therapeutic target in the context of respiratory fungal diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.